loading
전일 마감가:
$0.714
열려 있는:
$0.692
하루 거래량:
17,945
Relative Volume:
0.02
시가총액:
$4.27M
수익:
-
순이익/손실:
$-6.07M
주가수익비율:
-0.1197
EPS:
-5.78
순현금흐름:
$-7.34M
1주 성능:
+2.11%
1개월 성능:
+3.72%
6개월 성능:
-32.15%
1년 성능:
-59.05%
1일 변동 폭
Value
$0.692
$0.70
1주일 범위
Value
$0.6638
$0.74
52주 변동 폭
Value
$0.5759
$3.00

Adial Pharmaceuticals Inc Stock (ADIL) Company Profile

Name
명칭
Adial Pharmaceuticals Inc
Name
전화
434-422-9800
Name
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Name
직원
7
Name
트위터
@AdialPharma
Name
다음 수익 날짜
2024-12-12
Name
최신 SEC 제출 서류
Name
ADIL's Discussions on Twitter

ADIL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ADIL
Adial Pharmaceuticals Inc
0.692 4.27M 0 -6.07M -7.34M -5.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.26 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.28 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
630.12 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.89 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
248.70 24.70B 3.81B -644.79M -669.77M -6.24

Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-14 개시 Rodman & Renshaw Buy
2018-10-30 개시 Maxim Group Buy
2018-10-11 개시 Dawson James Buy

Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스

pulisher
Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 09, 2025

Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 09, 2025

Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 08, 2025

Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

Adial Pharma stock hits 52-week low at $0.6 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Adial Pharma stock hits 52-week low at $0.6 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 02, 2025

Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire

Apr 02, 2025
pulisher
Mar 31, 2025

Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com

Mar 31, 2025
pulisher
Mar 31, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World

Mar 31, 2025
pulisher
Mar 21, 2025

Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com

Mar 11, 2025
pulisher
Mar 08, 2025

Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World

Mar 08, 2025
pulisher
Mar 05, 2025

Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Adial Pharmaceuticals expects cash to fund operations into 2H of 2025 - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Can Adial's FDA-Approved Strategy for Alcohol Treatment Offset Its Widening Losses? - StockTitan

Mar 04, 2025
pulisher
Mar 02, 2025

Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 59.2% - The AM Reporter

Mar 02, 2025
pulisher
Mar 02, 2025

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World

Mar 02, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - accessnewswire.com

Feb 27, 2025
pulisher
Feb 27, 2025

Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia

Feb 26, 2025
pulisher
Feb 26, 2025

Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL.com

Feb 26, 2025
pulisher
Feb 26, 2025

Adial gets FDA nod for Phase 3 drug strategy - Investing.com India

Feb 26, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Adial Pharmaceuticals Advances AD04 with FDA Approval - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Benzinga

Feb 25, 2025
pulisher
Feb 23, 2025

Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City - ACCESS Newswire

Feb 23, 2025
pulisher
Feb 21, 2025

Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire

Feb 21, 2025
pulisher
Feb 20, 2025

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Adial Pharmaceuticals secures patent for genetic addiction treatment By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - GlobeNewswire

Feb 19, 2025
pulisher
Feb 16, 2025

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire

Feb 16, 2025

Adial Pharmaceuticals Inc (ADIL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
자본화:     |  볼륨(24시간):